Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cogent

17.64
+0.08500.48%
Volume:198.16K
Turnover:3.47M
Market Cap:866.25M
PE:-4.34
High:17.95
Open:17.49
Low:17.32
Close:17.55
52wk High:85.18
52wk Low:15.96
Shares:49.12M
Float Shares:47.97M
Volume Ratio:0.49
T/O Rate:0.41%
Dividend:4.02
Dividend Rate:22.82%
EPS(TTM):-4.0643
EPS(LYR):-4.2848
ROE:-136.94%
ROA:-2.47%
PB:-22.12
PE(LYR):-4.12

Loading ...

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

GlobeNewswire
·
Nov 14

Cogent Communications Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Nov 14

Cogent Communications on Track for Lowest Close Since June 2012 -- Data Talk

Dow Jones
·
Nov 14

Stock Track | Cogent Communications Plummets 5.08% as Multiple Analysts Slash Price Targets

Stock Track
·
Nov 13

Cogent Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 13

RBC Cuts Price Target on Cogent Communications Holdings to $23 From $40, Keeps Sector Perform Rating

MT Newswires Live
·
Nov 13

RBC Capital Remains a Hold on Cogent Comms (CCOI)

TIPRANKS
·
Nov 13

Cogent Biosciences Expects $547 Million in Net Proceeds From Equity, Convertible Notes Offerings

MT Newswires Live
·
Nov 13

U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare

Reuters
·
Nov 13

Director Sheryl Lynn Kennedy Reports Sale of Cogent Communications Holdings Inc. Common Shares

Reuters
·
Nov 13

Cogent Biosciences Prices $475 Million in Combined Equity, Convertible Notes Offerings

MT Newswires Live
·
Nov 12

Cogent Communications Is Maintained at Neutral by Citigroup

Dow Jones
·
Nov 12

Wedbush Upgrades Cogent Biosciences to Outperform From Neutral, Raises Price Target to $38 From $13

MT Newswires Live
·
Nov 11

Cogent Biosciences Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Nov 11

U.S. Small Caps Move Upward; Cogent Biosciences Leads Increases

Dow Jones
·
Nov 11

Cogent announces $200M convertible senior notes, $200M common stock offerings

TIPRANKS
·
Nov 11

Press Release: Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Dow Jones
·
Nov 11

Cogent Biosciences: Promising Outlook with Breakthrough GIST Treatment and Strategic Growth Plans

TIPRANKS
·
Nov 11

Cogent Biosciences’ Bezuclastinib Shows Promising Phase 3 Results, Boosting Buy Rating and Price Target

TIPRANKS
·
Nov 11

Cogent Biosciences price target raised to $50 from $18 at Leerink

TIPRANKS
·
Nov 11